> DBV Technologies priced a $150 million (€121 million) stock offering. The round precedes a planned submission for approval of a peanut allergy therapy in the U.S. Statement
> Motif Bio delayed a filing for approval of its antibiotic, iclaprim. The biotech now plans to submit an application to the FDA in the second quarter. Release
> Bavarian Nordic entered into a collaboration with the U.S. Department of Defense to develop a vaccine against the equine encephalitis virus. The deal is worth up to $36 million (€29 million). Statement
> Shield Therapeutics outlined the analyses it presented to the FDA at a pre-NDA meeting. The pivotal trial missed its hematology-focused primary endpoint, but Shield thinks the result was affected by confounding data. Shield is now waiting to learn the FDA’s take. Release
> Arix Bioscience raised £87 million ($123 million) from new and existing investors. The financing will enable Arix to add to the 13 investments it has made so far. Statement
> Deinove secured an option on Redx Pharma’s bacterial topoisomerase inhibitor program. The deal gives Deinove nine months to evaluate the program before deciding whether to pay a fee to exercise its option. Release